Pharmafile Logo

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.

- PMLiVE

Welcome to Delta – the new Fishawack Health magazine.

We’ve chosen to focus our first edition of the magazine on a topic close to our hearts, rare diseases.

Rare diseases represent an incredibly high unmet need, not only due to the lack of therapies and the practical difficulties in diagnosis, but also in patients’ desire for better knowledge, communication, and more meaningful relationships with their healthcare professionals.

As our rare disease specialist agency Dudnyk says: “We are seeing a growing separation between healthcare professionals and patients. The impact of this great divide in understanding is negatively affecting the treatment experience—for both sides—as well as severely limiting the trajectory of specialty healthcare brands.”

The dynamic between patients and healthcare professionals, combined with the challenges of patient identification and data generation in tiny patient populations (made even more challenging in a global pandemic), means rare disease drug development and launch requires a unique business model.

In this edition of Delta, our consultants, creatives and medical communications experts explore the challenges and opportunities for life science companies operating in rare disease, including:

  • Navigating real-world evidence and why it could be a gamechanger in rare disease
  • A patient’s account of living with a rare disease in the COVID-19 pandemic
  • How to make an impact in small patient populations
  • The lessons Dan Zaksas, PhD, Senior Vice President, Director of Scientific and Medical Affairs at Dudnyk, has learned during a decade working in rare diseases
  • Why you need to build relationships with KOLs and patients much earlier than you think
  • The lasting implications of COVID-19 on the life science industry.

DOWNLOAD THE MAGAZINE HERE

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.